Ignite Creation Date:
2025-12-25 @ 2:35 AM
Ignite Modification Date:
2026-02-27 @ 5:16 PM
Study NCT ID:
NCT03486834
Status:
COMPLETED
Last Update Posted:
2024-01-23
First Post:
2018-03-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-04-30
Start Date Type:
ACTUAL
Primary Completion Date:
2020-10-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-30
Completion Date Type:
ACTUAL
First Submit Date:
2018-03-28
First Submit QC Date:
None
Study First Post Date:
2018-04-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-10-01
Results First Submit QC Date:
None
Results First Post Date:
2021-11-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-19
Last Update Post Date:
2024-01-23
Last Update Post Date Type:
ACTUAL